Vibegron, mirabegron, and other add-on therapies for persistent overactive bladder symptoms in α1-blocker-treated men with benign prostatic hyperplasia: a systematic review and Bayesian network meta-analysis.
World J UrolSep 28, 2026 (epub)
Shugo Yajima, Gaku Okumura, Soichiro Yoshida et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and Bayesian network meta-analysis evaluated the efficacy and safety of vibegron, mirabegron, and other add-on therapies for overactive bladder symptoms in men with benign prostatic hyperplasia already treated with α1-blockers. Vibegron significantly reduced micturitions per 24 hours by 0.81 compared to control, while mirabegron reduced them by 0.46. Indirect comparisons did not show a clear advantage of vibegron over mirabegron.
Key findings
- Vibegron reduced micturitions per 24 h by 0.81 compared to control.
- Vibegron decreased urgency episodes per day by 0.96 versus control.
- Mirabegron reduced micturitions by 0.46 per 24 h compared to control.
- Indirect estimates showed no significant difference between vibegron and mirabegron.
Why it matters
Understanding the comparative effectiveness of add-on therapies for overactive bladder in men with benign prostatic hyperplasia is crucial for optimizing treatment strategies and improving patient outcomes.